Neurodevelopment –New genetic insights and therapeutic approaches are becoming available to inform drug discovery for diseases or disorders that stem from abnormal development in the early stages of life。 This informs our neurodevelopmental portfolio,which is focused on neuromuscular diseases,intellectual disabilities,and epileptic encephalopathies。 Neuropsychiatry –We are investigating the genetic drivers and brain circuitry underlying psychiatric conditions to better understand how the brain functions in adulthood,after development,to develop potential therapies for neuropsychiatric conditions such as bipolar disorder,depression,and schizophrenia。 Neurodegeneration and neuroinflammation –We want to better understand how the brain resists injury and ages healthfully over the lifespan to better understand neurodegeneration and neuroinflammation–two interconnected processes that contribute to disease in the aging brain。 Several new pathways and biomarkers have emerged in recent years that are shaping medicines we are developing for Alzheimer’s disease,Parkinson’s disease,frontotemporal dementia,progression in MS and rare monogenic neurodegenerative diseases。